Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VHB937 in early Alzheimer's disease
jRCT2031250510Active, not recruiting
- Sponsor
- Novartis
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Randomised, double-blind trial of VHB937 in Alzheimer's disease (AD) (3 arms), sponsored by Novartis. Primary endpoint: Change from baseline to Week 72 in Clinical Dementia Rating scale - Sum of Boxes. Started Dec 2025; status: active, not recruiting.
02
Drugs
VHB937
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2031250510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250510.